Laxative drug products for over-the-counter human use; psyllium ingredients in granular dosage forms. Final rule.
The Food and Drug Administration (FDA) is issuing a final rule establishing that over-the-counter (OTC) laxative drug products in granular dosage form containing the bulk-forming psyllium ingredients (psyllium (hemicellulose), psyllium hydrophilic mucilloid, psyllium seed, psyllium seed (blond), psyllium seed husks, plantago ovata husks, and plantago seed) are not generally recognized as safe and effective (GRASE) and are misbranded. This final rule includes, but is not limited to, any granules that are swallowed dry prior to drinking liquid; dispersed, suspended, or partially dissolved in liquid prior to swallowing; chewed, partially chewed, or unchewed, and then washed down (or swallowed) with liquid; or sprinkled over food. FDA is issuing this final rule after considering reports of esophageal obstruction associated with the use of psyllium laxatives in granular dosage form. These cases continue to occur despite efforts to promote safe use through label warnings and directions. This final rule does not apply to psyllium laxatives in nongranular dosage forms, such as powders, tablets, or wafers. This final rule is part of FDA's ongoing review of OTC drug products.
D002400:Cathartics / Q000009:adverse effects* / Q000627:therapeutic use; D003257:Consumer Product Safety; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D006801:Humans; D004366:Nonprescription Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011620:Psyllium / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States
D002400:Cathartics; D004366:Nonprescription Drugs; D011620:Psyllium